Aghajanian GK and BS Bunney (1973) Central dopaminergic neurons: neurophysiological identification and responses to drugs, In:Frontiers in Catecholamine Research (Usdin E and SH Snyder, Eds) (Pergamon Press, Great Britain), pp 643.
Anden NE, A Carlsson, A Dahlstrom, K Fuxe, NA Hillarp and K Larsson (1964) Demonstration and mapping-out of nigro-neos-triatal dopamine neurons.Life Sci. 3, 523.
Anden NE, A Dahlstrom, K Fuxe and K Larsson (1966) Functional role of the nigro-neostriatal dopamine neurons.Acta Pharmacol. Toxicol. (Copenh.) 24, 263–274.
Anden NE, SG Butcher, H Corrodi, K Fuxe and U Ungerstedt (1970) Receptor activity and turnover of dopamine and nora-drenaline after neuroleptics.Eur. J. Pharmacol. 11, 303–314.
Andreasen NC (2000) Schizophrenia: the fundamental questions.Brain Res. Brain Res. Rev. 31, 106–112.
Angrist B (1994) Clinical variations of amphetamine psychosis, In:Amphetamine and its Analogs: Psychopharmacology, Toxicology, and Abuse (Cho AK and DS Segal, Eds.) (Academic Press, New York, NY), pp 387–414.
Angrist B, G Sathananthan, S Wilk and S Gershon (1974) Amphetamine psychosis: behavioral and biochemical aspects.J. Psychiatr. Res. 11, 13–23.
Angrist B, H Thompson, B Shopsin and S Gershon (1975) Clinical studies with dopamine-receptor stimulants.Psychopharmacologia (Berl.) 44, 273–280.
Bezard E, S Ferry, U Mach, L Leriche, T Boraud, H Stark, C Gross and P Sokoloff (2003) Attenuation of levodopa-induced dyskine-sia by normalizing dopamine D3 receptor function.Nat. Med. 6, 762–767.
Bordet R, S Ridray, S Carboni, J Diaz, P Sokoloff and J-C Schwartz (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.Proc. Natl. Acad. Sci. USA 94, 3363–3367.
Carlsson A (1965) Drugs which block the storage of 5-hydrox-ytryptamine and related amines, In:Handbook of Experimental Pharmacology (Eicher O and A Farah, Eds.) (Springer-Verlag, Berlin), pp 561.
Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacol.1, 179–186.
Carlsson A and M Lindqvist (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain.Acta Pharmacol. Toxicol. 20, 140–144.
Carlsson A, K Fuxe, B Hamberger and M Lindqvist (1966) Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons.Acta Physiol. Scand. 67, 481–497.
Carta AR and CR Gerfen (1999) Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice.Neuroscience 90, 1021–1029.
Creese I and DR Sibley (1980) Receptor adaptations to centrally acting drugs.Annu. Rev. Pharmacol. Toxicol. 21, 357–391.
Creese I, DR Burt and SH Snyder (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischiz-ophrenic drugs.Science 192, 481–483.
Crow TJ (1982) The biology of schizophrenia.Experientia 38, 1276–1282.
Delay J, P Denicker and JM Harl (1952) Utilisation en thérapeu-tique psychiatrique d’une phénothiazine d’action centrale élective (4560 RP).Ann. Med. Psychol. 110, 112–117.
Diaz J, D Lévesque, N Griffon, CH Lammers, M-P Martres, P Sokoloff and J-C Schwartz (1994) Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens.Eur. J. Neurosci. 6, 1384–1387.
Diaz J, D Lévesque, CH Lammers, N Griffon, M-P Martres, J-C Schwartz and P Sokoloff (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor.Neuroscience 65, 731–745.
Diaz J, C Pilon, B Le Foll, C Gros, A Triller, J-C Schwartz and P Sokoloff (2000) Dopamine D3 receptors expressed by all mesen-cephalic dopamine neurons.J. Neurosci. 20, 8677–8684.
Farde L, FA Wiesel, C Halldin and G Sedvall (1988a) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.Arch. Gen. Psychiatry 45, 71–76.
Farde L, FA Wiesel, P Jansson, G Uppfeldt, A Wahlen and G Sedvall (1988b) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.Psychopharmacology (Berl.) 94, 1–7.
Farde L, FA Wiesel, AL Nordström and G Sedval (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.Psychopharmacology 99, S28-S31.
Farde L and AL Nordstrom (1993) PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs.Psychopharmacol. Ser. 10, 94–100.
Fessler RG, RD Sturgeon and HY Meltzer (1980) Effects of phen-cyclidine and methylphenidate on d-amphetamine-induced behaviors in reserpine-pretreated rats.Pharmacol. Biochem. Behav. 13, 835–842.
Fishburn CS, C David, S Carmon and S Fuchs (1994) The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain.FEBS Lett. 339, 63–66.
Freeman AS and BS Bunney (1984) The effects of phencyclidine andN-allynomethazocine on midbrain dopamine neuronal activity.Eur. J. Pharmacol. 104, 287–293.
French ED, C Pilapil and R Quirion (1985) Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyper-activity are decreased following lesions of the mesolimbic dopamine system.Eur. J. Pharmacol. 116, 1–9.
Goff DC and JT Coyle (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.Am. J. Psychiatry 158, 1367–1377.
Guillin O, J Diaz, P Carroll, N Griffon, J-C Schwartz and P Sokoloff (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.Nature 411, 86–89.
Guo N, MA Klitenick, CS Tham and HC Fibiger (1995) Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain.Neuroscience 65, 747–756.
Gurevich EV, Y Bordelon, RM Shapiro, SE Arnold, RE Gur and JN Joyce (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia.Arch. Gen. Psychiatry 54, 225–232.
Hall H, C Halldin, D Dijkstra, H Wikstrom, LD Wise, TA Pugsley, P Sokoloff, S Pauli, L Farde and G Sedvall (1996) Autoradiographic localisation of D3 dopamine receptors in human brain using the selective receptor agonist (+)-[3H]PD 128907.Psychopharmacology 128, 240–247.
Heimer L (2000) Basal forebrain in the context of schizophrenia.Brain Res. Brain Res. Rev. 31, 205–235.
Ital T, A Keskiner, N Kiremitci and JMC Holde (1967) Effect of phencyclidine in chronic schizophrenics.Can. Psychiatric Assoc. J. 12, 209–212.
Javitt DC and SR Zukin (1991) Recent advance in the phencycli-dine model of schizophrenia.Am. J. Psychiatry 148, 1301–1308.
Jentsch J and R Roth (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.Neuropsychopharmacology 20, 201–225.
Kapur S and D Mamo (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors.Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1081–1090.
Kline NS (1954) Use of Rauwolfia serpentina Benth. in neuropsy-chiatric conditions.Ann. NY Acad. Sci. 59, 107–132.
Kongsamut S, JE Roehr, J Cai, HB Hartman, P Weissensee, LL Kerman, L Tang and A Sandrasagra (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors.Eur. J. Pharmacol. 317, 417–423.
Kramer MS, B Last, A Getson and SA Reines (1997) The effect of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia.Arch. Gen. Psychiatry 54, 567–572.
Lahti RA, RC Roberts and CA Tamminga (1995) D2-family receptor distribution in human postmortem tissue: an autoradiograph-ic study.NeuroReport 6, 2505–2512.
Landwehrmeyer B, G Mengod and JM Palacios (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain: a comparative study usingin situ hybridization histochemistry and ligand binding autoradiography.Eur. J. Neurosci. 5, 145–153.
Laruelle M (2000) The role of endogenous sensitization in the pathology of schizophrenia: implications from recent brain imaging studies.Brain Res. Rev. 31, 371–384.
Laruelle M and A Abi-Dargham (2003) Dopamine imbalances in the schizophrenic brain: imaging studies, In:Dopamine Receptors and Transporters (Sidhu A, M Laruelle and P Vernier, Eds.) (Marcel Dekker Inc., New York), pp 593–642.
Laruelle M, A Abi-Dargham, CH van Dyck, R Gil, CD D’Souza, J Erdos, E McCance, W Rosenblatt, C Fingado, SS Zoghbi, RM Baldwin, JP Seibyl, JH Krystal, DS Charney and RB Innis (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.Proc. Natl. Acad. Sci. USA 93, 9235–9240.
Le Foll B, H Francès, J Diaz, J-C Schwartz and P Sokoloff (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice.Eur. J. Neurosci. 15, 2016–2026.
Le Moine C and B Bloch (1996) Expression of D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with D1 and D2 dopamine receptors.Neuroscience 73, 131–143.
Lecrubier Y (2003) A partial D3 receptor agonist in schizophrenia.Eur. Neuropsychopharmacol. 13 Suppl. 4, S167-S168.
Leriche L, J-C Schwartz and P Sokoloff (2003) The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.Neuropharmacology 45, 174–181.
Lévesque D, M-P Martres, J Diaz, N Griffon, CH Lammers, P Sokoloff and J-C Schwartz (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.Proc. Natl. Acad. Sci. USA 92, 1719–1723.
Malmberg A, DM Jackson, A Eriksson and N Mohell (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B and D3 receptors.Mol. Pharmacol. 43, 749–754.
Mathé JM, GG Nomikos, BE Hildebrand, P Hertel and TH Svensson (1996) Prazosin inhibits MK-801-induced hyperloco-motion and dopamine release in the nucleus accumbens.Eur. J. Pharmacol. 309, 1–11.
Meador-Woodruff JH, DK Grandy, HHM Van Tol, SP Damask, KY Little, O Civelli and SJ Watson (1994) Dopamine receptor gene expression in the human medial temporal lobe.Neuropsychopharmacol.10, 239–248.
Missale C, SR Nash, SW Robinson, M Jaber and MG Caron (1998) Dopamine receptors: from structure to function.Physiol. Rev. 78, 189–225.
Mohel N, M Sallemark, S Rosqvist, A Malmberg, T Hogberg and DM Jackson (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.Eur. J. Pharmacol. 6, 121–125.
Morissette M, M Goulet, R Grondin, P Blanchet, PJ Bedard, T Di Paolo and D Levesque (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.Eur. J. Neurosci. 10, 2565–2573.
Murase S, JM Mathé, J Grenhoff and TH Svensson (1992) Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activi-ty:differential actions on firing pattern related to anatomical localization.J. Neural Transm. 91, 13–25.
Murray AM, HL Ryoo, E Gurevich and JN Joyce (1994) Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain.Proc. Natl. Acad. Sci. USA 91, 11271–11275.
Newman-Tancredi A, V Audinot, C Chaput and MJ Millan (1997) [35S]Guanosine-5′-O-(3-thio)trophosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.J. Pharmacol. Exp. Ther. 282, 181–191.
Nyback H and G Sedvall (1970) Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain. Effect of some phenothiazine analogues.Eur. J. Pharmacol. 10, 193–205.
Ross CA and GD Pearlson (1996) Schizophrenia, the heteromodal association neocortex and development: potential for a neuroge-netic approach.Trends Neurosci. 19, 171–176.
Ryoo HL, D Pierrotti and JN Joyce (1998) Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson’s disease.Mov. Disord. 13, 788–797.
Sautel F, N Griffon, P Sokoloff, J-C Schwartz, C Launay, P Simon, J Costentin, A Schoenfelder, F Garrido, A Mann and CG Wermuth (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.J. Pharmacol. Exp. Ther. 275, 1239–1246.
Schoemaker H, Y Claustre, D Fage, L Rouquier, K Chergui, O Curet, A Oblin, F Gonon, C Carter, J Benavides and B Scatton (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.J. Pharmacol. Exp. Ther. 280, 83–97.
Schwartz J-C, J Diaz, C Pilon and P Sokoloff (2000) Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions.Brain Res. Brain Res. Rev. 31, 277–287.
Seeman P and T Lee (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.Science 188, 1217–1219.
Seeman P, T Lee, M Chau-Wong and K Wong (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors.Nature 261, 717–719.
Seeman P, C Ulpian, C Bergeron, P Riederer, K Jellinger, E Gabriel, GP Reynolds and WW Tortelotte (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics.Science 225, 728–731.
Snyder SH (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.Am. J. Psychiatry 133, 197–202.
Snyder SH (1980) Phencyclidine.Nature 285, 355–356.
Sokoloff P, B Giros, M-P Martres, ML Bouthenet and J-C Schwartz (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.Nature 347, 146–151.
Sokoloff P, M Andrieux, R Besançon, C Pilon, M-P Martres, B Giros and J-C Schwartz (1992) Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line: comparison with D2 receptor.Eur. J. Pharmacol. Mol. Pharmacol. Sect. 225, 331–337.
Sokoloff P, J Diaz, D Levesque, C Pilon, V Dimitriadou, N Griffon, CH Lammers, M-P Martres and J-C Schwartz (1995) Novel dopamine receptor subtypes as targets for antipsychotic drugs.Ann. NY Acad. Sci. 757, 278–292.
Susuki M, YL Hurd, H Hall, P Sokoloff, J-C Schwartz and G Sedvall (1998) D3 dopamine receptor mRNA is widely expressed in the human brain.Brain Res. 779, 58–74.
Svensson TH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drug.Brain Res. Brain Res. Rev. 31, 320.
Tarazi FI, WJ Florijn and I Creese (1997) Differential regulation of dopamine receptors after chronic typical and atypical antipsy- chotic drug treatment.Neuroscience 78, 985–996.
Usiello A, JH Baik, F Rouge-Pont, R Picetti, A Dierich, M LeMeur, PV Piazza and E Borrelli (2000) Distinct functions of the two isoforms of dopamine D2 receptors.Nature 408, 199–203.
Wong EHF, JA Kemp, T Priestley, AR Knight, GN Woodruff and LL Iversen (1986) The anticonvulsivant MK-801 is a potentN-methyl-D-aspartate antagonist.Proc. Natl. Acad. Sci. USA 83, 7104–7108.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4